Clinical trials
Advanced Malignant Cancer clinical trials
Below are recruiting advanced malignant cancer clinical trials, each written for real people, not researchers. We’re tracking 1,520 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07822919RecruitingPhase 1
Study of AWT020 for advanced solid tumors
This trial tests an investigational drug called AWT020 for people with advanced solid tumors that have grown after standard treatment. The goal is to see if AWT020 can help shrink or control the cancer, and it might be an option for you if other treatments haven't worked or aren't suitable.
Plantation, FloridaAges 18 years+ - NCT06079112RecruitingPhase 1/Phase 2
New drug combo for advanced bladder cancer
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07730190RecruitingPhase 1
Study of TQB6426 for advanced solid tumors
This study tests an investigational drug called TQB6426 for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called GPC3 found on some tumor cells. The goal is to see if the drug is safe and effective.
Hefei, AnhuiAges 18–75 - NCT07639450RecruitingPhase 1/Phase 2
N-3C01 Cancer Treatment Study for Advanced Solid Tumors
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
Saint Leonards, New South WalesAges 18–75 - NCT06718946RecruitingEarly Phase 1
IV IDOV-SAFE for advanced solid tumors: safety and effect study
This trial tests a new drug called IDOV-SAFE given through a vein. It is for people with advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug is safe and if it can help shrink tumors.
ShanghaiAges 18–75 - NCT06464055RecruitingPhase 1/Phase 2
A study of GQ1010 for advanced solid tumors
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
BeijingAges 18 years+ - NCT07326488RecruitingPhase 1/Phase 2
Study of MHB009C for advanced solid tumors
This trial tests a new drug called MHB009C for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07222267RecruitingPhase 1
Study of BG-75202 for advanced solid tumors
This trial tests a new drug called BG-75202, alone or with other drugs, for people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. It may offer a new option when other treatments have failed.
Birmingham, AlabamaAges 18 years+ - NCT06196736RecruitingPhase 3
Comparing a new drug to chemo for advanced bladder cancer
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06990464RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Fuzhou, FujianAges 18–75 - NCT06963814RecruitingPhase 1
HC006 with a PD-1 inhibitor for advanced solid tumors
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06298058RecruitingPhase 1
SIBP-A13 injection for advanced solid tumors
This trial tests a new drug called SIBP-A13 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for different cancer types, including lung, breast, and head and neck cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04409860Recruiting
Adjuvant chemo after chemoradiation for advanced cervical cancer
This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05173272RecruitingPhase 3
Immunotherapy plus chemo, then radiation, for advanced cervical cancer
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
Chengdu, SichuanAges 18 years+ - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT05315167RecruitingPhase 1/Phase 2
Study drug PRJ1-3024 for advanced solid tumors
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Zhengzhou, HenanAges 18 years+ - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT05869682RecruitingPhase 2
Bright light therapy for fatigue and depression in prostate cancer
This Phase 2 study tests whether a “bright white light” intervention can reduce cancer-related fatigue and depression in people with advanced prostate cancer receiving hormone-based treatment. If it works, it could improve day-to-day well-being while you’re on standard cancer therapies.
Duarte, CaliforniaAges 60 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant cancer?
- Yes. Clin2 currently lists 1,520 recruiting advanced malignant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.